## WEST.

## **End of Result Set**

Generate Collection

**Print** 

L3: Entry 1 of 1

File: USPT

Jul 31, 2001

DOCUMENT-IDENTIFIER: US 6268390 B1

\*\* See image for Certificate of Correction \*\*

TITLE: Therapeutic inhibitor of vascular smooth muscle cells

US Patent No. (1):

6268390

Detailed Description Text (28):

As referred to herein, a "cytostatic agent" includes moieties capable of inhibiting one or more pathological activities of target cells for a time sufficient to achieve a therapeutic benefit.

Detailed Description Text (63):

For the sustained release dosage form embodiments of the present invention, therapeutic agents preferably are those that inhibit vascular smooth muscle cell activity without killing the cells (i.e., cytostatic therapeutic agents). Another way to define a cytostatic agent is a moiety capable of inhibiting one or more pathological activities of the target cells for a time sufficient to achieve a therapeutic benefit. Preferred therapeutic agents for this purpose exhibit one or more of the following capabilities: to inhibit DNA synthesis prior to protein synthesis inhibition or to inhibit migration of vascular smooth muscle cells into the intima. These therapeutic agents do not significantly inhibit protein synthesis (i.e., do not kill the target cells) and, therefore, facilitate cellular repair and matrix production to stabilize the vascular wall lesion caused by angioplasty, by reducing smooth muscle cell proliferation.